SURVEY OF MOUTH-DISSOLVING TURMERIC LOZENGES IN HEALTHCARE WORKERS

ASSESSMENT OF CLINICAL ACCEPTABILITY OF MOUTH-DISSOLVING TURMERIC LOZENGES IN HEALTHCARE WORKERS INVOLVED IN COVID-19

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2020/05/025317

Enrollment

300

Registered

2020-05-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: TURMGEL MOUTH DISSOLVING LOZENGE 100 MG: EACH SOFT GELATINE LOZENGE CONTAINS TURMERIC EXTRACT 100 MG 3 LOZENGES DAILY FOR 1 MONTH. SUCK SLOWLY

DO NOT CHEW Control Intervention1: Not applicable: Not applicable

Eligibility

Inclusion criteria

Inclusion criteria: Healthcare professionals and paramedic staff serving COVD-19 will be enrolled in the study. Inclusion criteria: a. All adult individuals of both sexes working in COVID-19 wards. b. Individuals willing to give informed consent c. Individuals with no prior history of COVID-19 infections d. Individuals currently not showing any symptoms of COVID-19 at the time of recruitment e. Individuals with no history and / or currently ongoing serious chronic health condition f. Willing to follow the protective majors as advised g. Willing to comply with the study protocol

Exclusion criteria

Exclusion criteria: a. Any history of allergy to turmeric and /or any of the ingredients used in making of the lozenge. b. Refusal for informed consent. c. Concurrent ongoing other infections. d. Any current medical history that investigator may consider not advisable to work in COVID-19 ward.

Design outcomes

Primary

Measure	Time frame
Clinical acceptability of turmeric lozenges in COVID-19 healthcare teamsTimepoint: DAY 15 (follow up 1) and DAY 30 (end of study) are evaluation time points.	—

Secondary

Measure	Time frame
Safety and tolerance of turmeric lozengesTimepoint: End of study period at D 30	—

Countries

India

Contacts

Public ContactDR MANJUSHA RAJARSHI

Consultant, Gelnova Labs India Pvt Ltd.

manjusharajarshi@gmail.com9820315688

Outcome results